You are here:
Size
Please consult these documents on line if possible:
However, if you do need to order documents, please check the version you wish to order, complete the contact form and click on the “submit” button.
The company’s policy is to provide investors who so request a hard copy of documents containing its audited financial statements free of charge.
Please complete the following form (* indicates required fields):
The Sanofi Individual shareholder handbook completes the collection of information tools dedicated to individual shareholders.
It gives an overview of Sanofi in facts and figures, and provides information about how to manage your shareholdings and about our relationship with our shareholders. As this information isn’t exhaustive, we invite our readers to visit the website for further details or to contact the shareholder relations team for more specific questions.
Editorials: Serge Weinberg and Christopher A. Viehbacher comment on the 2011 results. Financial News: 2011 Annual results. News: 5 new products progressing to regulatory reviews; Rare diseases: Framingham site cleared by FDA and EMA; Warp Drive Bio and the innovative biotechnology; Fight against malaria; Partnership against 5 neglicted tropical diseases; Human vaccines; Combined general meeting 2012 resolutions. Zoom: Voting via Internet for General meeting.
Editorials: Serge Weinberg and Christopher A. Viehbacher comment on the third quarter 2011 performance News: new clinical study results in multiple sclerosis and type 2 diabetes ; Polio eradication ; Research collaboration for acne vaccine ; Eloxatin® patent litigation in the U.S. ; Positive benefit-risk balance of Multaq® confirmed Growth Platforms: Animal Health Financial News: Third quarter 2011 results Zoom: Site visit with the Shareholders Committee
Editorials: Serge Weinberg and Christopher A. Viehbacher comment on the second quarter 2011 performance and long term outlook. News: Sanofi announces new long term objectives ; Divestment of the Dermik dermatology unit ; Progress in R&D ; New research collaborations. Event: Strategy & Outlook - Investor Relations Thematic Seminar. Financial News: Second quarter 2011 results. Zoom: Visit our new Web site.
This new issue of the Letter focuses on latest news about acquisitions and partnerships, our oncology pipeline and Corporate Social Responsibility, first quarter 2011 results, the shareholders' general meeting and Sanofi's leading position in Emerging Markets.
This procedure is intended to protect Sanofi against automatically generated e-mails.
What is the third letter of the word 'diabetes' from the right?
Sanofi is committed to protecting the privacy of visitors. Your email and its content will be used to provide you with an answer to your message. We will not send you any unsolicited materials. You have the possibility to access, to modify, to rectify and to suppress any personal data concerning you. For more information we invite you to read the paragraph 4.1 of our legal notice.
© Sanofi 2004-2012 - All rights reserved - Update: May 04, 2012
